Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors
The purpose of this study is to determine if nivolumab and ipilimumab are effective treatment for people with pituitary tumors have gotten worse after surgery and radiation.
Pituitary|Pituitary Tumor|Pituitary Carcinoma|Pituitary Cancer
DRUG: Ipilimumab|DRUG: Nivolumab|DRUG: Nivolumab
Radiographic response rate, Radiographic response rate will be assessed by RANO/iRANO, 36 weeks from baseline
Safety as assessed by CTCAE 5.0, Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0 will be used to assess safety, 36 weeks from baseline
The purpose of this study is to determine if nivolumab and ipilimumab are effective treatment for people with pituitary tumors have gotten worse after surgery and radiation.